Balyasny Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Balyasny Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-30,000	Closed	-$1.2M	–	1490
2015 Q3	$1.2M	Buy	+30,000	New	+$978K	0.01%	716

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's ITCI Position: Q2 2025 in Review

Balyasny Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,257,912 shares — an estimated $298M sold.

Balyasny Asset Management first reported a position in ITCI in Q2 2015 and held it in 18 quarters. The position peaked at $298M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Balyasny Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Balyasny Asset Management sold 2,257,912 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $298M.
Balyasny Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2015 and held it in 18 quarters.
Balyasny Asset Management's Intra-Cellular Therapies Inc. position peaked at $298M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.